Dr. Leonard Joseph Appleman, MD

Dr. Appleman practices at UPMC Magee-Womens Hospital in Pittsburgh, Pennsylvania, part of University of Pittsburgh Medical Center.

Dr. Appleman's NPI, 1861468589, was assigned on February 23, 2006. Dr. Appleman graduated from New York University School of Medicine in 1995. Dr. Appleman holds Pennsylvania license 428996.

Dr. Appleman's primary practice is UPMC Magee-Womens Hospital, at 300 Halket Street, Pittsburgh, PA 15213 in Allegheny County. The practice phone is (412) 641-4010.

Dr. Appleman's primary practice is UPMC Magee-Womens Hospital in Pittsburgh, Pennsylvania, part of University of Pittsburgh Medical Center. Dr. Appleman is also affiliated with UPMC Presbyterian. The medical group on file is University of Pittsburgh Physicians, Department of Radiology. Dmand AI also links Dr. Appleman to 3 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Appleman practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Appleman's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Appleman is board certified in medical oncology by the American Board of Internal Medicine. Dmand AI has Dr. Appleman's licenses on file in 2 states: Pennsylvania and Massachusetts.

Dmand AI lists breast cancer, colorectal cancer, lymphoma, multiple myeloma and prostate cancer among the conditions Dr. Appleman treats.

CMS data shows 488 Medicare services from Dr. Appleman across 7 procedure codes in 2024, for 212 Medicare patients. Medicare paid $43,033 for them.

CMS counts 212 Medicare patients who saw Dr. Appleman in 2024. The largest group is 65 to 74, with 119 patients. 75% of them have cancer, and 69% have high blood pressure. Their average risk score is 2.11, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Appleman's median patient age at 74, with 11% women.

In 2024, Dr. Appleman wrote 1,933 Medicare Part D claims for 242 patients. 71% of them were for generic drugs. CMS names the drug for 1,693 of them, across 29 drugs with 11 or more claims each, at $7,309,788 in total drug cost. In 2023, CMS named 1,604 claims across 29 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 81 out of 100 for Dr. Appleman for performance year 2024, reported as part of a group. Dr. Appleman accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Appleman as offering telehealth.

Dmand AI links 98 papers to Dr. Appleman, published from 2006 to 2024. 2016 was the busiest year, with 8. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Renal Cell and Kidney Neoplasms. Dr. Appleman has published most often in Cancer Chemother Pharmacol. Dr. Appleman's most frequent co-authors are Toni K. Choueiri, MD, Rahul Atul Parikh, MD, PhD and Ronald G. Stoller, MD.

Dmand AI links Dr. Appleman to 20 clinical trials, 11 of them phase 2 studies. 9 are still active or recruiting. Conditions studied include Prostatic Neoplasms, Prostatic Diseases and Carcinoma, Renal Cell. National Cancer Institute (NCI) sponsors the most, 12.

CMS Open Payments shows 50 general payments to Dr. Appleman from 14 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 42% of the total. Pfizer Inc. paid the most, $9,738. It also lists 5 research payments totaling $9,070 from 2020 to 2022.

Dmand AI lists 1 award for Dr. Appleman, most recently Regional Top Doctor in 2014.

Dr. Appleman graduated from New York University School of Medicine in 1995.

Dr. Appleman is in network with 18 carriers, including Aetna, HCSC and United Healthcare. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.